Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05625399 · ClinicalTrials.gov registry record · Phase 3
A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma
A Phase 3 study of Melanoma, sponsored by Bristol-Myers Squibb.
- Active
- Registry status
- Phase 3
- Development phase
- 579
- Enrollment target
- 20
- Study locations
NCT05625399 is a Phase 3 study of Melanoma that is active but no longer recruiting, run by Bristol-Myers Squibb. The registered enrollment target is 579 participants, below the 704-participant average among 266 other Melanoma trials with a reported enrollment target (18% lower). The trial reports 20 study locations across 13 states.
The verdict
NCT05625399, a Phase 3 study of Melanoma, is active but no longer recruiting, sponsored by Bristol-Myers Squibb.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 579 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to demonstrate that the study drug exposure level of the nivolumab + relatlimab FDC subcutaneous (SC) formulation is not worse than nivolumab + relatlimab FDC intravenous (IV) administration in participants with previously untreated metastatic or unresectable melanoma.
Conditions Studied
Interventions
- DRUG Nivolumab + Relatlimab
- DRUG rHuPH20
Study Locations (20)
New South Wales
- Local Institution - 0050 - Coffs Harbour
- Local Institution - 0175 - Orange
- Local Institution - 0172 - Port Macquarie
- Local Institution - 0118 - Wagga Wagga
- Local Institution - 0184 - Waratah
California
- Local Institution - 0098 - Los Angeles
- Local Institution - 0093 - Orange
- Local Institution - 0123 - Stanford
Pennsylvania
- Local Institution - 0139 - Easton
- Local Institution - 0124 - Philadelphia
Arizona
- Local Institution - 0125 - Phoenix
Arkansas
- Local Institution - 0189 - Springdale
Colorado
- Local Institution - 0113 - Englewood
Florida
- Local Institution - 0114 - Jacksonville
Maryland
- Local Institution - 0146 - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 579 participants |
| Start Date | 2023-03-06 |
| Est. Completion | 2027-11-18 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05625399
The ClinicalTrials.gov registry entry for NCT05625399 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 579 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 704-participant average among 266 other Melanoma trials with a reported enrollment target (18% lower). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Melanoma appearing as the primary indexed condition, and to 2 interventions - of which Nivolumab + Relatlimab is the first listed.
NCT05625399 reports 20 study locations spanning 13 distinct geographic areas - top geographies include New South Wales, California, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05625399 about?
NCT05625399 is a clinical study titled "A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma". The purpose of this study is to demonstrate that the study drug exposure level of the nivolumab + relatlimab FDC subcutaneous (SC) formulation is not worse than nivolumab + relatlimab FDC intravenous (IV) administration in participants with previously untreated metastatic or unresectable melanoma.
What is the current status of trial NCT05625399?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 579 participants. The study started on 2023-03-06. Estimated completion is 2027-11-18.
What conditions does trial NCT05625399 study?
This clinical trial studies the following conditions: Melanoma.
What interventions are being tested in trial NCT05625399?
The interventions under investigation include: Nivolumab + Relatlimab (DRUG), rHuPH20 (DRUG).
Who is sponsoring clinical trial NCT05625399?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05625399 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
RECRUITING · Phase 3
-
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
RECRUITING · Phase 3
-
Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy
ACTIVE NOT RECRUITING · Phase 3
-
A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)
ACTIVE NOT RECRUITING · Phase 3
-
A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma
ACTIVE NOT RECRUITING · Phase 3
-
Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.